"In-House" Data on the Outside-A Mobile Health Approach.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
11
10
2019
accepted:
03
01
2020
pubmed:
20
1
2020
medline:
28
10
2020
entrez:
20
1
2020
Statut:
ppublish
Résumé
Mobile health (mHealth) technologies have the potential to capture dense patient data on the background of real-life behavior. Merck & Co., Inc. (Kenilworth, NJ), in collaboration with Koneksa Health, conducted a phase I clinical trial to validate cardiovascular mHealth technologies for concordance with traditional approaches and to establish sensitivity to detect effects of pharmacological intervention. This two-part study enrolled 18 healthy male subjects. Part I, a 5-day study, compared mHealth measures of heart rate (HR) and blood pressure (BP) to those from traditional methods. Hypotheses of similarity, in the clinic and at home, were tested individually for HR, systolic BP, and diastolic BP, at a 2-sided 0.05 alpha level, with a prespecified criterion for similarity being the percentage differences between the 2 measurements within 15%. Part II, a 7-day, 3-period randomized balanced crossover study, evaluated the mHealth technology's ability to detect effects of bisoprolol and salbutamol. Hypotheses that the changes from baseline in HR were greater in the bisoprolol (reduction in HR) and salbutamol (increase in HR) groups compared with no treatment were tested, at a 1-sided 0.05 alpha level. Linear mixed-effects models, Pearson's correlation coefficients, summary statistics, and exploratory plots were applied to analyze the data. The mHealth measures of HR and BP were demonstrated to be similar to those from traditional methods, and sensitive to changes in cardiovascular parameters induced by bisoprolol and salbutamol.
Substances chimiques
Antihypertensive Agents
0
Albuterol
QF8SVZ843E
Bisoprolol
Y41JS2NL6U
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
948-956Informations de copyright
© 2020 Merck Sharp & Dohme Corp. Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.
Références
Frewer, P., Mitchell, P., Watkins, C. & Matcham, J. Decision-making in early clinical drug development. Pharm. Stat. 15, 255-263 (2016).
Nahm, M.L., Pieper, C.F. & Cunningham, M.M. Quantifying data quality for clinical trials using electronic data capture. PLoS One 3, e3049 (2008).
Izmailova, E.S., Wagner, J.A. & Perakslis, E.D. Wearable devices in clinical trials: hype and hypothesis. Clin. Pharmacol. Ther. 104, 42-52 (2018).
Wexler, D. & Bertelsen, K.M. A brief survey of first-in-human studies. J. Clin. Pharmacol. 51, 988-993 (2011).
Kalsbeek, A. et al. SCN outputs and the hypothalamic balance of life. J. Biol. Rhythms 21, 458-469 (2006).
Scheer, F.A. et al. Impact of the human circadian system, exercise, and their interaction on cardiovascular function. Proc. Natl. Acad. Sci. USA 107, 20541-20546 (2010).
Veerman, D.P., Imholz, B.P., Wieling, W., Wesseling, K.H. & van Montfrans, G.A. Circadian profile of systemic hemodynamics. Hypertension 26, 55-59 (1995).
Somers, V.K., Dyken, M.E., Mark, A.L. & Abboud, F.M. Sympathetic-nerve activity during sleep in normal subjects. N. Engl. J. Med. 328, 303-307 (1993).
Kraft, V. & Leone, F. Asthma and chronic obstructive pulmonary disease. In: Pharmacology and Therapeutics Principles to Practice 1st edn., (eds. Waldman, S.A. & Terzig, A.). 417-434 (Saunders Elsevier (Saunders, an Imprint of Elsevier, Inc.), Philadelphia, PA, 2009).
Rutherford, J., Braunwald, E. & Cohn, P. Chronic Ischemic Heart Disease. In: Heart Disease - A Textbook of Cardiovascular Medicine 3rd edn., (ed. Braunwald, E.). 1314-1378 (W.B. Saunders Company, Harcourt Brace Jovanovich, Inc., Philadelphia, PA, 1988).
Department of Health & Human Services. Preventice BodyGuardian® 510(k) clearance. 2015 <https://www.accessdata.fda.gov/cdrh_docs/pdf15/K151188.pdf>.
Department of Health & Human Services. A&D UA-767PBT 510(k) clearance. 2015 <https://www.accessdata.fda.gov/cdrh_docs/pdf4/K043217.pdf>.
Stoschitzky, K., Stoschitzky, G., Brussee, H., Bonelli, C. & Dobnig, H. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 106, 199-206 (2006).
Kurosawa, N., Owada, E., Kato, A., Bando, K., Ito, K. & Kurosawa, S. Serum concentration and cardiovascular effects of salbutamol after oral and rectal administration in healthy volunteers. J. Clin. Pharm. Ther. 18, 103-108 (1993).
Silke, B., Hanratty, C.G. & Riddell, J.G. Heart-rate variability effects of beta-adrenoceptor agonists (xamoterol, prenalterol, and salbutamol) assessed nonlinearly with scatterplots and sequence methods. J. Cardiovasc. Pharmacol. 33, 859-867 (1999).
Schliep, H.J. & Harting, J. Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs. J. Cardiovasc. Pharmacol. 6, 1156-1160 (1984).
U.S. Product Circular: EMCOR (Bisoprolol fumarate) film-coated tablets <https://www.drugs.com/uk/emcor-ls-5mg-tablets-leaflet.html>. (2012).
Morgan, D.J., Paull, J.D., Richmond, B.H., Wilson-Evered, E. & Ziccone, S.P. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br. J. Clin. Pharmacol. 22, 587-593 (1986).
Willey, R.F., Grant, I.W. & Pocock, S.J. Effects of oral salbutamol and pirbuterol on FEV1, heart rate and blood pressure in asthmatics. Br. J. Clin. Pharmacol. 3, 595-600 (1976).
Burstyn, P., O'Donovan, B. & Charlton, I. Blood pressure variability: the effects of repeated measurement. Postgrad. Med. J. 57, 488-491 (1981).
Daimee, U., Done, D., Tu, X., Bisognano, J. & Bayer, W. The utility of repeating blood pressure measurements in the primary care office: “first pass” white coat hypertension. J. Am. Soc. Hypertens. 9, e39-e40 (2015).